BioCatalystWatch
KYTXWorkspace / KYTX / OverviewCompany library
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. (KYTX)

Website

Price
Market cap
Next catalystAt ASH 2026, December 12–15; session date not suppliedMiv-cel — KYSA-8 / stiff person syndrome · Data readoutCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

KYV-101

CD19

PreINDP1P2P3FilingApproved
KYV-101

CD19

PreINDP1P2P3FilingApproved

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

KYV-101

CD19

PreINDP1P2P3FilingApproved
KYV-101

CD19

PreINDP1P2P3FilingApproved

Other pipelines

KYV-201

CD19

PreINDP1P2P3FilingApproved

History / paused

CD19

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

KYTX PR & News

PR & News

KYTX SEC archive